S. Y. Archer, J. Johnson, H. J. Kim, Q. Ma, H. Mou, V. Daesety, S. Meng and R. A. Hodin, “The Histone Deacetylase Inhibitor Butyrate Down Regulates Cyclin B1 Gene Expression via a p21/WAF-1-Dependent Mechanism in Human Colon Cancer Cells,” American Journal of Physiology—Gastrointestinal and Liver Physiology, Vol. 289, No. 4, 2005, pp. 696-703.

has been cited by the following article:

• TITLE: Evaluation of the Antitumor and Radiosynthetizing Activity of a Novel Quinoline Sulfonamide Derivative (PIQSA) as a Histone Deacetylase Inhibitor

  AUTHORS: Eman Noaman, Nadia Fahmy, Raafat Yousri, Omama El Shawi, Maha Ghazy

  KEYWORDS: Antitumor, Radiosynthetization, Quinoline Derivative, Sulfonamide Moiety, HDACI, Apoptosis, Cell Cycle, DNA Fragmentation

  JOURNAL NAME: Journal of Cancer Therapy, Vol.2 No.4, October 12, 2011

  ABSTRACT: Inhibition of histone deacetylases (HDACs) is emerging as a new strategy in cancer therapy. In the present work a novel pyrimido-quinoline benzene sulfonamide (PIQSA compound) was designed and synthesized postulating its ability to inhibit HDAC enzyme in cancer cells. This study was designed to examine the in vitro anti-tumor efficacy of PIQSA against Ehrlich Ascite carcinoma cells (EAC) and three of the human cancer cell lines (H460), brain (U251) and liver (HepG2). The results of Cytotoxic assays showed that PIQSA exhibited in vitro antitumor activity in a dose dependant manner. The tumor growth delay studies indicating that PIQSA resulted in significant regression in tumor growth, which was more pronounced when PIQSA treatment accompanied with radiation exposure. Also, the efficacy of PIQSA to influence radiation response in Ehrlich solid carcinoma (ESC) tumors was estimated. The results suggest that PIQSA exhibited antitumor activities and strong radioenhancing properties associated with inhibition of HDAC activity, DNA fragmentation followed by apoptotic cell death, preferential cell loss of cells particularly in G1/G0 phase through an apoptotic pathway.